Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
What a crazy 4 months it has been! Today we announced that @RecursionPharma & @exscientiaAI shareholders have overwhelmingly approved the proposed business combination! Behind the scenes, our teams have been hard at work planning for a successful close and then to continue… https://t.co/9rzRFZL8zF
Exscientia $EXAI and Recursion $RXRX merger approved by shareholders. 🚀 https://t.co/DXNOwHaqgF
On Nov. 20, join the call! Today we announced that Recursion and Exscientia shareholders have approved the proposed business combination. On Wed., Nov. 20, 7:30am ET / 5:30am MT / 12:30pm GMT, we’re holding a special update call to discuss the next chapter of Recursion after the… https://t.co/iN3FNzNzav
Recursion Pharmaceuticals and Exscientia have received shareholder approval for their proposed merger, as announced on November 13, 2024. The approval was confirmed by both companies, with Recursion planning a special update call on November 20 at 7:30 AM ET to discuss the merger's implications and the future direction of the combined entity. The merger is seen as a significant step for both companies, which have been collaborating on advancements in open science and artificial intelligence in drug discovery. The approval marks the culmination of four months of planning and negotiations between the two firms.
